Drug intelligence / Profile preview

mAb42

Development stage: Preclinical
Lead developer: Mapp Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular

Overview

**mAb42** is an investigational, intramuscularly administered three-monoclonal-antibody cocktail being developed by Mapp Biopharmaceutical and its commercialization arm, LeafBio, as a potential pan-ebolavirus medical countermeasure. The program was listed as a lead candidate in IND-enabling development for prophylactic use. The individual antibodies, their exact viral epitopes, and the precise cocktail composition have not been publicly disclosed.

Other names: 3-mAb cocktail

Beyond the preview

Go deeper on mAb42.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb42.

Explore the full profile